Rise Advisors’s Veracyte VCYT Stock Holding History

Rise Advisors’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-305	Closed	-$10.5K	–	1372
2025 Q3	$10.5K	Hold	305	–	–	﹤0.01%	966
2025 Q2	$8.24K	Hold	305	–	–	﹤0.01%	1078
2025 Q1	$9.04K	Buy	+305	New	+$11.6K	﹤0.01%	1042

Other funds holding VCYT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Rise Advisors's VCYT Position: Q4 2025 in Review

Rise Advisors sold out of Veracyte (VCYT) in Q4 2025, closing a stake of 305 shares — an estimated $10.5K sold.

Rise Advisors first reported a position in VCYT in Q1 2025 and held it in 3 quarters. The position peaked at $10.5K in Q3 2025. 329 funds tracked by Wall St. Rank hold VCYT as of Q4 2025.

Rise Advisors reported no remaining Veracyte position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 305 Veracyte shares in Q4 2025, an estimated $10.5K.
Rise Advisors first reported a position in Veracyte in Q1 2025 and held it in 3 quarters.
Rise Advisors's Veracyte position peaked at $10.5K in Q3 2025.
329 funds tracked by Wall St. Rank held Veracyte as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.